Hideho Okada

University of California, San Francisco

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Jessica Schulte

Assistant Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES

View details

Sujan Shresta

La Jolla Institute for Allergy and Immunology

UNITED STATES

View details

Noriyuki Kasahara

Chief Scientific Officer

UNITED STATES

View details

Takahide Nejo

University of California, San Francisco

UNITED STATES

View details

Sergio Quezada

University College London

UNITED KINGDOM

View details

Vinay Puduvalli

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ryusuke Hatae

Assistant Professor

Kyushu University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hideho Okada

Research Interests

Explore related searches

Contact this professor

Articles (18)

The T-cell receptor repertoire: A window into pediatric brain tumor immunity

Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations

Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment

Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier

Activating the dark genome to illuminate cancer vaccine targets

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immischet al

Current Advances in Immunotherapy for Glioblastoma.

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade

The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment

Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy

Collaborators (7)

Jessica Schulte

Sujan Shresta

Noriyuki Kasahara

Takahide Nejo

Sergio Quezada

Vinay Puduvalli

Ryusuke Hatae

Make your next move.